November 16, 2026
Source: drugdu
45

On November 13, the official website of the National Medical Products Administration (NMPA) showed that the marketing application of the generic drug Chidamide tablets submitted by Nanjing Chia Tai Tianqing Pharmaceutical was approved, making it the first company in China to obtain approval for the generic version of this drug.
Chidamide is a domestically developed Class 1.1 new drug independently developed by Shenzhen Chipscreen Biosciences and approved for marketing in 2014. In recent years, with the expansion of indications and coverage by medical insurance, the market size of this drug has continued to grow. In 2025, its sales in domestic hospitals reached 595 million yuan, making it an anti-tumor drug with a market size of nearly 600 million yuan.
Nanjing Chia Tai Tianqing Pharmaceutical Group has become the first company in China to obtain approval for the production and marketing of generic versions of Chidamide tablets, officially obtaining the qualification for the generic drug. This also means that this nearly 600 million yuan market has a new competitor.
The original drug has annual sales of nearly 600 million yuan and has been approved for three indications in China.
Chidamide is a novel molecular entity drug with a novel mechanism discovered exclusively by Chipscreen Biosciences, and it is also the world's first subtype-selective histone deacetylase (HDAC) inhibitor.
Currently, Chidamide has been approved for three indications in China, covering the treatment of diffuse large B-cell lymphoma, peripheral T-cell lymphoma, and breast cancer.
From a market performance perspective, this product has already formed a large-scale commercial market. According to Chipscreen Biosciences' 2025 annual report, Chidamide's sales reached 580 million yuan in 2025, an increase of approximately 16% year-on-year, mainly due to the inclusion of diffuse large B-cell lymphoma (DLBCL) as a new indication in medical insurance.
According to data from the Moshang Pharmaceutical Database, the sales of Chidamide in domestic hospitals reached 595 million yuan in 2025, a year-on-year increase of 2.58%; and the sales reached 251 million yuan in the first three quarters of 2026.
Chia Tai Tianqing Pharmaceutical Group wins first generic version of a blockbuster drug with sales of 600 million yuan.
In terms of R&D progress, Nanjing Chia Tai Tianqing Pharmaceutical Group initiated a bioequivalence (BE) trial for Chidamide tablets in December 2024 , covering the following two indications:
This drug is indicated for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one prior course of systemic chemotherapy. This indication was granted conditionally based on the objective response rate results of a single-arm clinical trial. Long-term survival benefits from this drug have not been established, and confirmatory clinical trials with randomized controlled designs are ongoing.
Combined aromatase inhibitors are used for patients with hormone receptor-positive, human epidermal growth factor receptor-2-negative, postmenopausal, locally advanced or metastatic breast cancer that has relapsed or progressed after endocrine therapy.
The product completed clinical trials in March 2025, subsequently submitted an application for generic drug marketing authorization, and was approved on November 13, 2026.
To date, only Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has submitted a marketing application and received approval in the domestic generic version of Chidamide tablets , becoming the first company in China to produce a generic version.
For a mature anti-tumor drug with annual hospital sales of nearly 600 million yuan, the approval of the first generic version means that the original product is no longer the only approved Chidamide tablet product in the domestic market. With the formal approval of the generic drug, the Chidamide market is also ushering in a new competitive landscape.
Nine generic drugs have been approved this year, and Chia Tai Tianqing is accelerating its product portfolio development.
The approval of the first generic version of Chidamide tablets is another step forward in Nanjing Chia Tai Tianqing's generic drug product development this year.
According to statistics, Nanjing Chia Tai Tianqing Pharmaceutical Group has had nine generic drugs approved for marketing this year. Among them, four products—Lvocarnitine chewable tablets, Pemafibrate tablets, Merogabalin besylate tablets, and Chidamide tablets—have achieved the first domestic approval.
From the breakthrough of becoming the first generic version of an original drug with nearly 600 million yuan in revenue, to the successive approvals of multiple generic drugs, Nanjing Chia Tai Tianqing Pharmaceutical Group is further enriching its product portfolio. The approval of the first generic version of Chidamide tablets adds a new product to its anti-tumor drug product line.
Source: https://mp.weixin.qq.com/s?__biz=MzkxMTM1MDMyMA==&mid=2247564721&idx=3&sn=bebd55391c0fae30bff45882c8831449&chksm=c08fe53b083acb23085ee5525b81dc581ec55c411016e77a5c02b904d09768718967a8e8f7bf&scene=126&sessionid=0#rd
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.